MedTrace Logo

Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation

NCT02710188 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2016-10-18

No results posted yet for this study

Summary

The purpose of this study is to find a modified release oral tablet formulation for this drug, which will be safe and well tolerated.

Conditions

Interventions

DRUG

HTL0009936 modified release

HTL0009936 modified release

DRUG

HTL0009936 immediate release

HTL0009936 immediate release

Sponsors & Collaborators

  • Quotient Clinical

    collaborator OTHER

  • Nxera Pharma UK Limited

    lead INDUSTRY

Principal Investigators

  • Litza McKenzie, MBChB · Quotient Clinical

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-07-31
Completion
2016-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02710188 on ClinicalTrials.gov